Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
What are the commercial prospects for biosimilar drugs? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
This study investigates biosimilars (follow-on biologics). It lets you assess forecasted sales at world market, therapeutic submarket and national level to 2022.
Our investigation gives you business research and analysis with sales forecasts and opinion.
You discover forecasting of six submarkets to 2022, finding potential biosimilar revenues and comparisons with the overall biologics market at category level:
• Monoclonal antibodies (MAbs) and fusion proteins
• G-CSF agents
• Growth hormones.
The new report gives you coverage of regulatory affairs too - FDA, EMA and others - assessing trends and outlooks for biosimilar drugs.
What will happen next? Our study shows you how biopharmaceutical competition will intensify. The R&D pipeline for follow-on biological drugs is strong and promising. Also, improved drug delivery will be important from 2012. You see how and why.
Patent expiry will erode blockbuster revenues in biopharma, creating many opportunities for biosimilars and related follow-on biologics. More than 20 blockbuster biologics will lose patent protection in the US by 2022.
High demand for more-affordable biological drugs will stimulate the market. We show you sales potentials there. You also see driving and restraining forces in that emerging industry.
What are biopharma companies doing? Our study discusses Sandoz, Teva, Dr. Reddy's, Wockhardt and others, evaluating prospects of the industry and market. You discover where leading companies are heading from 2012.
Many commercial opportunities for biosimilars and related products exist, with high revenues possible to 2022. Product launches will change the market. Our report shows and explains.
You can investigate biosimilar drugs now, discovering revenue potentials and other trends.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 80 tables, 67 charts and four research interviews.
Ten ways Biosimilars and Follow-On Biologics: World Market 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover market forecasting to 2022 for the US, Japan, the EU5 countries, China, India and South Korea
• Assess leading companies, discovering their activities and outlooks
• Explore approval pathways and regulatory guidelines for the US, the EU, Japan, China, India and South Korea
• Review R&D and product approvals, seeing pipelines and portfolios
• Find out when patents will expire on reference products
• See possible launch times for biosimilars, with discussions of potential
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, seeing interviews with external authorities.
There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Agence française de sécurité sanitaire des produits de santé (AFSSAPS) [France]
Beijing Shuanglu Medicine Co
Bioceuticals Arzneimittel (a subsidiary of Stada)
BioGeneriX (a subsidiary of ratiopharm)
Biopharmaceuticals and Herbal Medicines Bureau [South Korea]
Biotechnology Regulatory Authority of India (BRAI)
BresaGen (now part of Hospira)
Bristol-Myers Squibb (BMS)
Cardiovascular and Renal Drugs Advisory Committee [US]
cell pharm (a subsidiary of Stada)
Celltrion Healthcare (a subsidiary of Celltrion)
Centres of Medicare and Medicaid Services (CMS) [US]
Chiron (now part of Novartis)
Committee for Medicinal Products for Human Use (CHMP) [EU]
Compass Biotechnologies (formerly Cyplasin Biomedical)
Congressional Budget Office (CBO) [US]
Department of Biotechnology (DBT) [India]
Dr. Reddy's Laboratories
Eden Biodesign (a subsidiary of Watson Pharmaceuticals)
European Generic Medicines Association (EGA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Food and Drug Law Institute (FDLI) [US]
Fraunhofer Institute [Germany]
Fujifilm Pharma (a subsidiary of Fujifilm)
Genentech (now part of Roche)
Genetic Engineering Approval Council (GEAC) [India]
Genzyme (now part of Sanofi)
GlycoFi (now part of Merck & Co)
Hexal (a subsidiary of Novartis)
Hospira Japan (a division of Hospira)
Human Genome Sciences
Johnson & Johnson (J&J)
Korean Food and Drug Administration (KFDA)
Kyowa Hakko Kirin
LG Life Sciences (a division of LG)
Marvel Life Sciences
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Merck BioManufacturing Network (now part of Fujifilm)
Merck BioVentures (a division of Merck & Co)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
National Health Service (NHS) [UK]
National Institute for Biological Standards and Control (NIBSC) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute for the Control of Pharmaceutical and Biologic Products [China]
Oncologic Drug Advisory Committee (ODAC) [US]
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmasset (a subsidiary of Gilead)
ratiopharm (now part of Teva)
RBC Capital Markets
Recombinant DNA Advisory Committee (RDAC) [India]
Reliance GeneMedix (a subsidiary of Reliance Life Sciences)
Reliance Life Sciences (a division of Reliance Group)
Review Committee on Genetic Manipulation (RCGM) [India]
Samsung Bioepis (joint venture between Samsung BioLogics and Biogen Idec)
Samsung BioLogics (joint venture between Samsung and Quintiles)
Sandoz (part of Novartis)
Shanghai Celgen Bio-Pharmaceutical
Shantha Biotechnics (now part of Sanofi)
State Food and Drug Administration (SFDA) [China]
Teva Pharmaceutical Industries
Teva-Kowa Pharma (a subsidiary of Teva)
Therapeutic Goods Administration (TGA) [Australia]
World Health Organization (WHO)
Wyeth (now part of Pfizer)